First- and Second-Line Treatment for mCRC in Specific Populations

Second-Line Therapy for RAS Wild-Type mCRCПодробнее

Second-Line Treatment for mCRCПодробнее

Second-Line Therapy for RAS Wild-Type mCRCПодробнее

Maintenance and Second-Line Decisions in mCRCПодробнее

State-of-the-art first-line therapy for mCRCПодробнее

Debate: Salvage therapy for mCRC? - TAS-102 followed by regorafenibПодробнее

Onvansertib for second-line treatment of KRAS-mutated mCRCПодробнее

Deciding Second-Line Treatment for mCRCПодробнее

Second-Line Treatment Options in Metastatic Colorectal CancerПодробнее

BREAKWATER: encorafenib plus cetuximab in patients with BRAF V600E-mutant mCRCПодробнее

Maintenance Therapy for mCRCПодробнее

mCRC: Factors to Consider for First-Line TherapyПодробнее

Changing Realities in Treating mCRCПодробнее

Debate 1: First-line Treatment of Metastatic Colorectal Cancer - CALGB 80405Подробнее

Second-Line and Salvage Treatment of Metastatic Colorectal CancerПодробнее

Expert Report on panitumumab for first line treatment of RAS wild type mCRC from ASCO 2022Подробнее

Options for Second-Line Therapy in mCRCПодробнее

Dr. Bordonaro on First-Line Treatment Options for mCRCПодробнее

Exploring Second-Line Therapeutic Options in mCRCПодробнее